NC-LENOVO/FORMULA-1
10.3.2022 14:32:13 CET | Business Wire | Press release
Formula 1 and Lenovo announced today that Lenovo is an Official Partner ahead of the upcoming 2022 season. The multi-year deal will see Lenovo’s cutting-edge technology used across Formula 1’s operations as it continues to bring the highest-level of racing and entertainment to its worldwide fanbase. As global leaders in their respective fields, Formula 1 and Lenovo want to push the boundaries of what’s possible when combining sports with advanced technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005287/en/
Over the next few years, the partnership will involve Lenovo’s technology being used across the Formula 1 organization, both back at its base and at races. Lenovo’s hardware devices, as well as High Performance Computing and server solutions will be increasingly integrated throughout the organisation’s operations. From running powerful on-premises data collection solutions to producing higher quality content and supporting broadcast applications, the Formula 1 and Lenovo collaboration will result in a better experience for fans.
The partnership will drive global visibility of Lenovo, showcasing Lenovo’s capabilities on a global scale and integrating industry-leading hardware technology at the heart of Formula 1. It plans to leverage Lenovo’s extensive selection of premium hardware as well as innovative next-generation technology such as augmented and virtual reality, as F1 continues to connect fans with the sport in new and more engaging ways.
Earlier this year, F1 announced that it has extended its commitment to create employment and education opportunities for underrepresented groups, in the form of ten engineering scholarships each year through to 2025. Lenovo is also focused on diversity and inclusion and removing barriers, and through the partnership will work with F1 on projects related to this important area.
Stefano Domenicali, President & CEO of Formula 1, said:
“As we prepare for our record-breaking season, it is exciting to welcome Lenovo to the team and for us to join forces with a global leader in technology. Like everything in Formula 1, precision and detail are everything, and Lenovo will be at the forefront of providing their experience and innovative technologies to our operations throughout the season. Our fans expect the best from everything we do, and Lenovo is the perfect partner in terms of its premium hardware offerings. We are entering a new era of our sport and we’re committed to delivering a high-quality experience for our dedicated followers around the world.”
Yang Yuanqing, Chairman & CEO of Lenovo, said:
“We are proud to announce our new global partnership with Formula 1, the world’s most prestigious motor racing competition, to engage half a billion fans all over the world with exciting, innovative experiences. This partnership is based on our shared passion for innovation, performance, and the winning spirit. Together Lenovo and Formula 1 will push the limits of technology to help shape a faster, smarter, and more sustainable future.”
Luca Rossi, President of Intelligent Devices Group, Lenovo, said:
“Partnering with Formula 1 to deploy Lenovo’s smarter solutions across the organization, from base operations to the stunning excitement of the Grands Prix, will help push the boundaries of what is possible and transform the racing experience. Formula 1 is focused on its digital transformation and continuing to surprise and delight its fans. Lenovo’s portfolio of hardware, services and solutions will be key to helping Formula 1 create new ways for fans around the world to experience the same thrills you’d experience track side.”
About Formula 1®
Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: LSXMA, LSXMB, LSXMK, BATRA, BATRK, FWONA, FWONK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com , and read about the latest news via our StoryHub .
LENOVO is a trademark of Lenovo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom